Partnerships: Agfa & Premier; ART & GE; Philips & Bioscan
Agfa HealthCare has inked a three-year, dual source contract by Premier Purchasing Partners to provide computed radiography (CR) products to the alliance's 1,700 member hospitals and more than 43,000 other healthcare delivery sites. The Premier contract is estimated at approximately $35 million per year and names Agfa HealthCare as one of two preferred suppliers of CR technologies. Agfa’s entire line of CR hardware, software and service maintenance agreements is covered in this contract. Premier in a separate announcement named Fujifilm Medical Systems USA as its other CR partner.

ART Advanced Research Technologies announced the extension of its current agreement with GE Healthcare for the exclusive worldwide distribution of its eXplore Optix preclinical optical molecular imaging system. The existing 3-year agreement, executed in 2003, was set to expire on Dec. 31, 2006. The extension of the current distribution agreement will allow ART and GEHC to maintain the ongoing sales, marketing and customer support operations for eXplore Optix while the parties workout a new multi-year agreement.

Royal Philips Electronics and Bioscan announced that they have signed an agreement giving Philips Medical Systems co-marketing and co-distribution rights for Bioscan’s In-Vivo molecular imaging products, NanoSPECT and NanoSPECT/CT. The agreement covers countries in Europe, the Middle-East, Africa, Asia and Latin America. NanoSPECT, Bioscan’s preclinical imager uses multiplexed multi-pinhole (MMP) SPECT (single photon emission computed tomography) technology increasing the system sensitivity ten-fold and improves spatial resolution to the sub-millimeter range. NanoSPECT is capable of imaging study subjects at lower injected dose levels and images are obtained in minutes rather than hours, enabling dynamic SPECT. Using NanoSPECT, it is possible to look inside the organs of studied subjects with high-clarity functional images. Bioscan will continue to market and sell the NanoSPECT product line in the US and will continue to focus on the biotech and pharmaceutical market segment in Europe and other parts of the world.